Related Experiment Videos

[Interdisciplinary and evidence-based treatment guideline for juvenile idiopathic arthritis]

N Guellac1, T Niehues

  • 1Zentrum für Kinder und Jugendmedizin, HELIOS Klinikum Krefeld.

Klinische Padiatrie
|October 25, 2008
PubMed

Insights

Standardizing care for Juvenile Idiopathic Arthritis (JIA) through evidence-based recommendations can improve treatment quality for children and adolescents. This study established an updated interdisciplinary guideline for JIA management.

Area of Science:

  • Pediatric Rheumatology
  • Evidence-Based Medicine
  • Clinical Guideline Development

Background:

  • Juvenile Idiopathic Arthritis (JIA) treatment quality varies significantly among caregivers.
  • Standardization of JIA care is needed to improve outcomes for affected children and adolescents.
  • An updated, interdisciplinary, evidence-based treatment guideline for JIA was developed.

Framework:

  • Systematic literature analysis using PubMed (last 3 years, humans, clinical trials).
  • Exclusion of studies on JIA diagnosis, uveitis, vaccination, transition, and rofecoxib.
  • Inclusion of authors from the 2005 guideline and nominated society representatives.

Implementation:

  • Consensus conferences held with professional moderation.
  • Representatives from multiple pediatric and rheumatology societies attended.
  • Statements were confirmed using the Delphi method.

Implications:

  • Compiled consensus statements on drug therapy, symptomatic, and surgical management of JIA.
  • Statements strictly judged by Evidence-Based Medicine (EBM) criteria.
  • Aims to further improve the quality of care for children and adolescents with JIA.
Abstract

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...